Combination therapies against HIV-1 infection: exploring the concept of combining antiretroviral drug treatments with HIV-1 immune-based therapies in asymptomatic individuals.
The deleterious effect of HIV on the immune system begins at the time of infection. At seroconversion the virologic and immunologic factors that ultimately will dictate the rate of disease progression are believed to be already in place. The concept developed in this paper implies that, to impact significantly on the progression of disease, anti-HIV therapies should be initiated as early as possible in asymptomatic individuals. Published results have shown that combination drug therapies are potent in reducing HIV-1 RNA load in plasma in asymptomatic individuals, and that some HIV-1 immune-based therapies have a positive impact on immunological markers of disease progression, including HIV-1 cell-mediated immunity (CMI) and CD4 percent. The strategy discussed is to test a combination of antiretroviral therapy with HIV-1 immune-based therapy, such as the inactivated HIV-1 immunogen preparation, in asymptomatic individuals. The goal of this combination approach is to overcome the limitations of each therapy alone. Preliminary data suggest that antiretroviral therapy and the HIV-1 Immunogen can be combined with no noticeable interference and/or added toxicity in a broad range of HIV-1-infected individuals. Combining both therapies may enhance and expand the impact on key surrogate markers of disease progression, although they likely achieve this impact through different mechanisms. Thus, the primary question remains: Can these effects be synergistic?
Ferre
F
F
AIDS PATIENT CARE and STDs, Larchmont, NY 10538, USA.
Moss
R B
RB
Daigle
A E
AE
Trauger
R J
RJ
Richieri
S P
SP
Jensen
F C
FC
Carlo
D J
DJ
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D003131:Combined Modality Therapy; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D015497:HIV-1; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D016896:Treatment Outcome; D019562:Viral Load
D000276:Adjuvants, Immunologic; D019380:Anti-HIV Agents